wetenschapsdag 2023 | 105 Sessie 3d: Architecturale Hoogstandjes en Chirurgische Laagstandjes x2 Auteurs Y.A. Civil, J.E. Vasmel, R.K. Charaghvandi, A.C. Houweling, P.J. van Diest, A.J. Witkamp, A. Doeksen, T. van Dalen, H.M. Verkooijen, F. van der Leij, S. van der Velde, H.J.G.D. van den Bongard Abstract titel Pre-operative single dose partial breast irradiation: five-year results of the ABLATIVE trial Background In the ABLATIVE trial (NCT02316561), 15/36 patients achieved a pathologic complete response 6-8 months after preoperative single-dose partial beast irradiation (PBI). We now present the long-term outcomes of the ABLATIVE trial. Methods Between 2015 and 2018, 36 patients with low-risk breast cancer were treated with preoperative single-dose PBI followed by BCS after 6 (n=15) or 8 (n=21) months. Toxicity, quality of life and cosmetic outcome were scored at baseline and yearly visits until 5 years after preoperative PBI. Results After a median follow-up of 5.1 years (3.8–6.3 years), grade 1 breast fibrosis and breast discomfort/pain were present in 83% and 44% of the patients, respectively. Grade 2 breast fibrosis (3%) and fatigue (3%) at 3 years completely resolved at 5 years. Two (6%) patients developed ipsilateral breast events and two (6%) distant metastases. The five-year overall survival rate was 94%. The proportion of patients (very) satisfied with the cosmetic results was 89% and 76% at baseline and 5 years, respectively (p=0.2). The 4-year quality of life scores remained constant (90 (baseline) vs. 94 (4 years); p=0.9). Conclusion Preoperative single-dose PBI and BCS is an oncological safe treatment with mild late toxicity, and no decline in cosmetic results and quality of life during 5 years of follow-up. In the ongoing ABLATIVE-2 trial (NCT05350722), BCS is performed at 12 months after preoperative PBI aiming to achieve a higher pathologic response rate and response monitoring is performed using MRI and biomarkers.
RkJQdWJsaXNoZXIy MTk4NDMw